BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200922
DTEND;VALUE=DATE:20200925
DTSTAMP:20260515T113627
CREATED:20200615T080459Z
LAST-MODIFIED:20200615T080459Z
UID:25926-1600732800-1600991999@www.pharmajournalist.com
SUMMARY:11th World Bispecific Summit – Running Virtually for 2020
DESCRIPTION:Transforming to a digital platform for the eleventh year\, the World Bispecific Summit will continue to deliver a greater scope and penetration of innovative technical content than any other meeting. This year’s re-imagined agenda will cover unique discovery\, translational and manufacturing challenges faced in the bispecific field. Whatever your role and interest in the field\, you will leave the meeting with concrete methods to employ into your strategy and pipeline to convert the promise of bispecific therapeutics into a reality for patients. \n \nDiscover who the 40+ expert speakers are\, and the topics they will examine\, including how: \n\nMacroGenics are evaluating selection and format optimization of bispecific molecules for a simultaneous blockade of PD-1 and LAG-3 (MGD013) versus PD-1 and CTLA4 (MGD019)\nSound Biologics are pioneering their unique platform\, MabPair Technology for making bi-functional antibody\nInvenra demonstrates preclinical efficacy through the selective elimination of tumor Tregs\nIncyte and Adimab are enhancing the selectivity of bispecific approaches to reduce on-target off-tumor toxicities in solid tumor indications\nGenentech are showcasing how several factors such as epitope\, binding affinity\, format\, target expression\, etc.\, influence the design and development of T-cell bispecific for cancer immunotherapy\n\nDownload the event guide to find out more
URL:https://www.pharmajournalist.com/event/11th-world-bispecific-summit-running-virtually-for-2020/
LOCATION:Virtual Summit
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20200924
DTEND;VALUE=DATE:20200925
DTSTAMP:20260515T113627
CREATED:20200716T140226Z
LAST-MODIFIED:20200716T140226Z
UID:26355-1600905600-1600991999@www.pharmajournalist.com
SUMMARY:TIGIT Therapies Digital Consortium
DESCRIPTION:Priming the immune system against solid tumors by leveraging immune checkpoint blockade has proven to be an effective tool in multiple malignancies. \nFollowing the success of PD1/PDL1 checkpoint inhibitors a new wave of ICI now enters the clinic\, amongst which TIGIT has shown exciting preliminary results and sparked great excitement in this nascent field. With 27 ongoing clinical trials investigating TIGIT in front- and second-line indications\, a great deal of momentum has built in this competitive space. \n \nHowever\, core challenges must still be addressed by the community\, such as: \n\nInvestigating the TIGIT pathway\, ligands\, and modes of action\nOptimizing biomarker strategy to identify optimal patient populations and indications\nRationalizing combination strategy to leverage the TIGIT mechanise for maximum therapeutic benefit\n\nThe TIGIT Therapies Digital Consortium will gather the greatest minds in TIGIT research in a series of monthly\, themed seminars. Gain access to 1:1 time with leaders in TIGIT research and take away tangible learnings with monthly executive summaries and exclusive content after the event. \nIn such a fast-paced industry\, this is a unique opportunity to provide an overview of the ‘knowns and unknowns’ in the field and draw a path for best practice in the safe development of TIGIT therapies with maximum clinical impact. \nWorking with leaders in the industry we have developed a series of working groups that bring together the best and brightest minds within the development of TIGIT therapies to bring you the opportunity to share invaluable insights\, leverage the collective experiences of years of expertise and network and collaborate with the movers and shakers; all with the ultimate aim of accelerating the clinical to commercial development of TIGIT therapies. \nAt a time when we are more isolated than ever\, these working groups will break down barriers and provide the opportunity for frank and open discussion to ensure the continued progress and development of TIGIT therapies. \nHead to the TIGIT Therapies Digital Consortium website to access your complimentary event guide and find out more!
URL:https://www.pharmajournalist.com/event/tigit-therapies-digital-consortium-1/
LOCATION:Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR